Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Exploratory, Multicenter, Non Randomized, Single Agent Cohort Study to Determine Best Tumor Response With Trastuzumab Emtansine in HER2 Overexpressing Solid Tumors

NCT02999672 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02999672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02999672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Exploratory, Multicenter, Non Randomized, Single Agent Cohort Study to Determine Best Tumor Response With Trastuzumab Emtansine in HER2 Overexpressing Solid Tumors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
December 23, 2016
Completion date
April 10, 2018
Enrollment
20 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cholangiocellular carcinoma, pancreas cancer